ArticleAnnals of surgery2004
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.
Article in Annals of surgery, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 316 citations in OpenAlex.
- Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score.Updates in surgery · 2021Pooled it
- Preoperative evaluation of the histological grade of hepatocellular carcinoma with diffusion-weighted imaging: a meta-analysis.PloS one · 2015Pooled it
- Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies.PloS one · 2011Trial
- Multifaceted role of histopathology in liver transplantation for hepatocellular carcinoma: A narrative review towards precision prognosis.World journal of transplantation · 2026Article
- Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on "Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging".Clinical and molecular hepatology · 2024Article
- Differentiating Well-Differentiated from Poorly-Differentiated HCC: The Potential and the Limitation of Gd-EOB-DTPA in the Presence of Liver Cirrhosis.Diagnostics (Basel, Switzerland) · 2024Article
- Evolution of Liver Transplantation Indications: Expanding Horizons.Medicina (Kaunas, Lithuania) · 2024Review
- Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.Cancers · 2023Review
- Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review.Clinical and molecular hepatology · 2022Review
- Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?European journal of medical research · 2022Article
- Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade.Scientific reports · 2021Article
- Clinical outcomes of patients with two small hepatocellular carcinomas.World journal of hepatology · 2021Article
- Review
- Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review.Journal of clinical medicine · 2021Review
- Liver transplantation in malignant disease.World journal of clinical oncology · 2021Review
- Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion?Hepatobiliary surgery and nutrition · 2021Article
- Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience.Annals of gastroenterological surgery · 2020Review
- Recent advances in liver transplantation for cancer: The future of transplant oncology.JHEP reports : innovation in hepatology · 2019Review
- Controversies in the management of hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2019Review
- Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant.Annals of transplantation · 2019Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the long-term results of liver transplantation for well- or moderately differentiated hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: HCC patient selection for liver transplantation remains controversial, and deciding exclusively on the strength of criteria such as number and size of nodules appears prognostically inaccurate.
methodsSince 1991, preoperative tumor grading has been used at our center to establish whether a patient with HCC is fit for transplantation. Poorly differentiated HCC cases were excluded, while size and number of nodules were not considered as absolute selection criteria. Thirty-three patients with moderately or well-differentiated HCC were prospectively studied after liver transplantation. A group of 15 patients with incidental HCC transplanted during the same period were also evaluated and compared with the 33 patients with preoperatively diagnosed HCC.
resultsOn histologic examination, 38% of the entire group of 48 patients did not meet the "Milan criteria" and 42% were pTNM stages III and IV. The median follow-up was 44 months. The 5-year actuarial survival rate was 75% and recurrence-free survival was 92%. HCC recurred in only 3 patients (6%). The only histomorphologic variable differing significantly between incidental and nonincidental HCC was nodule size. The timing of diagnosis (incidental vs. nonincidental HCC), the Milan criteria, and the TNM stage revealed no statistically significant impact on overall and recurrence-free survival rates.
conclusionsThe routine pre-orthotopic liver transplantation tumor grading may represent a valid tool in the selection of unresectable HCC patients for transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.